GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEON Biopharma Inc (AMEX:AEON) » Definitions » Current Ratio

AEON Biopharma (AEON Biopharma) Current Ratio : 1.19 (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is AEON Biopharma Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. AEON Biopharma's current ratio for the quarter that ended in Sep. 2023 was 1.19.

AEON Biopharma has a current ratio of 1.19. It generally indicates good short-term financial strength.

The historical rank and industry rank for AEON Biopharma's Current Ratio or its related term are showing as below:

AEON' s Current Ratio Range Over the Past 10 Years
Min: 0.12   Med: 0.48   Max: 6.41
Current: 0.48

During the past 5 years, AEON Biopharma's highest Current Ratio was 6.41. The lowest was 0.12. And the median was 0.48.

AEON's Current Ratio is ranked worse than
90.11% of 1557 companies
in the Biotechnology industry
Industry Median: 3.73 vs AEON: 0.48

AEON Biopharma Current Ratio Historical Data

The historical data trend for AEON Biopharma's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEON Biopharma Current Ratio Chart

AEON Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
6.41 4.85 0.25 0.12 0.48

AEON Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Sep22 Dec22 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only 0.25 - 0.12 1.19 0.48

Competitive Comparison of AEON Biopharma's Current Ratio

For the Biotechnology subindustry, AEON Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AEON Biopharma's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's Current Ratio distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's Current Ratio falls into.



AEON Biopharma Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

AEON Biopharma's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=6.222/13.049
=0.48

AEON Biopharma's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=16.911/14.177
=1.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AEON Biopharma  (AMEX:AEON) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


AEON Biopharma Current Ratio Related Terms

Thank you for viewing the detailed overview of AEON Biopharma's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AEON Biopharma (AEON Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4040 MacArthur Boulevard, Suite 260, Newport Beach, CA, USA, 92660
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for therapeutic indications.
Executives
Strathspey Crown Holdings Group, Llc 10 percent owner 4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660
Priveterra Sponsor, Llc 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Daewoong Co., Ltd 10 percent owner 244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211
Alexander Blair Wilson officer: Exec VP, CLO & Corp Secretary 5 PARK PLAZA, SUITE 1750, IRVINE CA 92614
Chad Oh officer: Chief Medical Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Marc Forth director, officer: Chief Executive Officer C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660
Jost Fischer director C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Oleg Grodnensky 10 percent owner 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Vikram Malik 10 percent owner 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Peter A Reynolds officer: Chief Financial Officer 27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610
Robert J Palmisano director, 10 percent owner 110 HARTWELL AVENUE, LEXINGTON MA 02173
Shelley B Thunen director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric G Carter director C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Meredith officer: Chief Legal Officer&Secretary 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301